Patents by Inventor Jill Miller

Jill Miller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods related to protein displacement therapy for myotonic distrophy
    Patent number: 9371527
    Abstract: Disclosed are compositions and methods related to the interaction of polyCUG and polyCCUG repeat RNA and proteins that bind to these repetitive RNA sequences. Also disclosed are methods of treating DM1 or DM2 comprising inhibiting the interaction of poly(CUG)exp or poly(CCUG)exp RNA with muscleblind proteins, or by causing improvement of spliceopathy in myotonic dystrophy.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: June 21, 2016
    Assignee: University of Rochester
    Inventors: Charles A. Thornton, Thurman Wheeler, Krzysztof Sobczak, Robert Osborne, Jill Miller, Maurice Scott Swanson
  • Compositions and Methods Related to Protein Displacement Therapy for Myotonic Distrophy
    Publication number: 20150080452
    Abstract: Disclosed are compositions and methods related to the interaction of polyCUG and polyCCUG repeat RNA and proteins that bind to these repetitive RNA sequences. Also disclosed are methods of treating DM1 or DM2 comprising inhibiting the interaction of poly(CUG)exp or poly(CCUG)exp RNA with muscleblind proteins, or by causing improvement of spliceopathy in myotonic dystrophy.
    Type: Application
    Filed: June 5, 2014
    Publication date: March 19, 2015
    Inventors: Charles A. Thornton, Thurman Wheeler, Krzysztof Sobczak, Robert Osborne, Jill Miller, Maurice Scott Swanson
  • COMPOSITIONS AND METHODS RELATED TO PROTEIN DISPLACEMENT THERAPY FOR MYOTONIC DISTROPHY
    Publication number: 20100190689
    Abstract: Disclosed are compositions and methods related to the interaction of polyCUG and polyCCUG repeat RNA and proteins that bind to these repetitive RNA sequences. Also disclosed are methods of treating DM1 or DM2 comprising inhibiting the interaction of poly(CUG)exp or poly(CCUG)exp RNA with muscleblind proteins, or by causing improvement of spliceopathy in myotonic dystrophy.
    Type: Application
    Filed: September 21, 2007
    Publication date: July 29, 2010
    Applicants: University of Rochester, University of Florida Research Foundation, Inc.
    Inventors: Charles A. Thornton, Thurman Wheeler, Krzysztof Sobezak, Robert Osborne, Jill Miller, Maurice Swanson